CivicaScript Cuts Drug Costs by $16 Million in 2025

The 2025 savings were primarily fueled by the company’s flagship abiraterone acetate tablets, now marketed as Abirtega, alongside four additional specialty generics introduced throughout the year. While these newer products are still in the early stages of market adoption, they are already delivering significant reductions in per-claim costs. Data indicates that individual patients saved as much as 91% on specific claims, with out-of-pocket savings alone exceeding $400,000 for the year.

Payer members, who shoulder the bulk of total medicine expenditures, saw the most substantial financial relief, totaling $15.7 million. Savings per claim varied by product, with payers seeing an average benefit of $856 for abiraterone and up to $2,358 for newer specialty offerings. CivicaScript President Brent J. Eberle noted that the results validate the company's focus on transparency and collaboration across the manufacturing and distribution chain.

The organization is now scaling its reach, recently expanding into biosimilars with a low-cost private-label insulin glargine and the distribution of a Stelara biosimilar. As these therapies gain traction, the company expects the total financial impact to climb. By utilizing a "MaxRP" policy—a maximum recommended price printed on every package—CivicaScript aims to standardize costs and eliminate price gouging for essential treatments.